Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
IVVD
#2829
Invivyd, Inc. Common Stock
1.6
9
-1.17%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-1.17%
Changement Mensuel
-17.56%
Evolution sur 6 mois
+74.23%
Changement Annuel
+40.83%
Clôture Précédente
1.7
1
Open
1.6
9
Bid
Ask
Low
1.6
9
High
1.6
9
Volume
53
Marchés
Actions des Marchés US
Soins de Santé
IVVD
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
119.62 M
119.96 M
119.96 M
120.14 M
233.12 M
—
Valuation ratios
Enterprise value
15.14 M
-16.19 M
24.53 M
51 M
171.47 M
230.81 M
Price to earnings ratio
-0.52
-0.31
-0.51
-0.79
-2.39
-4
Price to sales ratio
—
2.07
1.97
1.85
2.85
8.73
Price to cash flow ratio
0.61
0.31
0.51
0.75
1.69
3.26
Price to book ratio
0.2
0.78
0.21
0.34
0.57
1.9
Enterprise value to EBITDA ratio
—
0.09
—
—
—
—
Profitability ratios
Return on assets %
0.38
0.14
0.16
0.16
0.08
0.54
Return on equity %
0.73
0.27
0.3
0.34
0.11
1.03
Return on invested capital %
2 627.35
362.64
229.4
201.48
143.5
937.02
Gross margin %
100
92.16
97.29
98.72
98.87
387.03
Operating margin %
670.01
139.14
149.7
127.78
83.96
500.58
EBITDA margin %
—
-141.74
—
—
—
—
Net margin %
653.11
133.45
144.1
124.38
79.75
481.68
Liquidity ratios
Quick ratio
1.58
1.21
1.02
0.76
1.9
4.88
Current ratio
1.92
1.62
1.53
1.33
2.47
6.95
Inventory turnover
—
0.04
0.01
0.01
0.01
0.06
Asset turnover
0.05
0.09
0.1
0.12
0.12
0.43
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
6.18
7.72
9.64
11.22
7.19
35.76
Long term debt to total equity ratio
12.02
14.81
18.47
23.37
10.74
67.39
Per share metrics
Operating cash flow per share
0.34
0.32
0.18
0.11
0.05
0.65
EBIT per share
—
-0.17
-0.14
-0.12
-0.06
-0.48
EBITDA per share
—
-0.17
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.89
0.58
0.4
0.29
0.5
1.78
Net current asset value per share
1.26
0.85
0.63
0.49
0.65
2.62
Tangible book value per share
0.7
0.57
0.45
0.36
0.55
1.92
Working capital per share
0.61
0.33
0.22
0.12
0.38
1.05
Book value per share
0.7
0.57
0.45
0.36
0.55
1.92
Nouvelles
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now? - TipRanks.com
La CHRO d’Invivyd Green vend pour 63.000$ d’actions après exercice d’options
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise
Le directeur scientifique d’Invivyd vend des actions pour 58.600$
Invivyd CSO Allen sells shares worth $58,600
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
H.C. Wainwright maintient sa recommandation d’achat sur l’action Invivyd suite aux retours de la FDA
H.C. Wainwright reiterates Buy rating on Invivyd stock amid FDA feedback
Invivyd reçoit les commentaires de la FDA sur son essai d’anticorps COVID vs vaccin ARNm
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial
H.C. Wainwright maintient sa recommandation d’achat sur Invivyd avant des données d’essai clés